TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05908877

Intervention type: OTHER
Intervention: History and Clinical evaluation
Description: HISTORY and CLINICAL EVALUATION and recording of the following parameters:~* Gestational Age~* Birth Weight~* Gender~* Weaning habits~* Anthropometric indices: actual age; actual weight; actual height; body mass index BMI (kg/m2) + percentile; waist circumference; age for height; weight for height; height for age; height standard deviation score (SDS)~* Vital parameters: heart rate (beats/min); respiratory rate (breaths/min); blood pressure (mmHg)~* Adipose tissue~* Subcutaneous fat tissue distribution~* Acanthosis Nigricans~* Stretch marks (striae)~* Tanner Puberty Stage
Study: NCT05634681

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Plan of the day
Description: Several treatment plans are prepared and the appropriate plan is used at each treatment session.
Study: NCT06463990

Intervention type: OTHER
Intervention: TyG index
Description: association between TyG index and triglyceride to high-density lipoprotein cholesterol ratio with fetal macrosomia

Intervention type: OTHER
Intervention: TyG index
Description: association between TyG index and triglyceride to high-density lipoprotein cholesterol ratio with fetal macrosomia
Study: NCT06151873

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Adapted sport
Description: control group sample, healthy subjects without musculoskeletal, neurological or vestibular alterations can participate.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Adapted sport
Description: Subjects with cerebral palsy/acquired brain damage belonging to the Spanish National Soccer Team with cerebral palsy and acquired brain damage may participate as an experimental group.
Study: NCT05634681

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard plan
Description: One treatment plan
Study: NCT06540820

Intervention type: DIAGNOSTIC_TEST
Intervention: Dexa or Biompedance analysis with clinical and biochemical evaluations
Description: All patients will undergo body composition study with DXA or Bioimpedance analysis which are the gold standard to determine % of fat mass and fat free mass, basal biochemical examinations and oral glucose tolerance test (OGTT), and clinical evaluation with waist circumference measurement. Moreover, all patients will undergo REMS ultrasound, TBS and BSI evaluation at DXA scan and hand grip test. In addition, all patients will undergo to clinical evaluation with specific nutritional, physical activity and sleep quality questionnaire assessments and an additional volume of blood.

Intervention type: DIAGNOSTIC_TEST
Intervention: Dexa or Biompedance analysis with clinical and biochemical evaluations
Description: All patients will undergo body composition study with DXA or Bioimpedance analysis which are the gold standard to determine % of fat mass and fat free mass, basal biochemical examinations and oral glucose tolerance test (OGTT), and clinical evaluation with waist circumference measurement. Moreover, all patients will undergo REMS ultrasound, TBS and BSI evaluation at DXA scan and hand grip test. In addition, all patients will undergo to clinical evaluation with specific nutritional, physical activity and sleep quality questionnaire assessments and an additional volume of blood.
Study: NCT06319573

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling Supported by Univfy® Report
Description: The intervention consists of patients being counseled with the Univfy® PreIVF report during their second consultation. They will also be asked to fill in the same anonymous online questionnaire.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Counseling
Description: Patients in this group will be counseled as per standard care during their second consultation. They will be asked to complete an anonymous online validated questionnaire (see below) to assess their responses to the anonymous online questionnaire after consultation.
Study: NCT05596552

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyperbaric bupivacaine and dexmedetomidine
Description: In a 3 ml syringe, 5 µg dexmedetomidine was added to the 2 ml of 10 mg hyperbaric bupivacaine, to have a total volume of 2.5 ml for intrathecal spinal injection over 3 minute without barbotage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-Fentanyl group
Description: In a 3 ml syringe, 25 μg fentanyl was added to the 2 ml of 10 mg hyperbaric bupivacaine, to have a total volume of 2.5 ml for intrathecal spinal injection over 3 minute without barbotage
Study: NCT05326997

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation group
Description: Participants will have their face sanitized with micellar water (a cosmetic product for cleaning and makeup remover), followed by cleaning with soap. Then, the eyes will be protected with gauze, proper glasses and a black towel on top, a headset with relaxation music will also be placed and then the face will receive the treatment with yellow light. After the session the face will receive sunscreen. A placebo cosmetic will be given to the participant to be applied twice a day and daily sunscreen.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group control (Tranexamic acid)
Description: Participants will have their face sanitized with micellar water. Then, the eyes will be protected with gauze, proper glasses and a black towel on top, a headset with relaxation music will also be placed and then the face will receive the treatment with yellow light sham. The person responsible for applying the PBM will simulate the irradiations by positioning the device in the same places described for the PBM group, however, the equipment will be kept off. After the session the face will receive sunscreen. Will be delivered to patients, liposomal tranexamic acid with use 2 x a day home care and daily sunscreen.
Study: NCT05903924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tradipitant
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tradipitant
Description: Oral Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Capsule
Study: NCT03544606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isosorbide mononitrate
Description: 40 mg tablet of intra-vaginal IMN (Effox; MINAPHARMA, Cairo, Egypt) will be placed into the posterior fornix of the vagina, through a digital vaginal examination, every 4 h for a maximum of four doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: In placebo group (group 2) 40 mg intra-vaginal pyridoxine placebos every 4 h for a maximum of four doses will be given
Study: NCT05149807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701 injection
Description: SHR-1701 injection Tegafur Gimeracil Oteracil Potassium Oxaliplatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Tegafur Gimeracil Oteracil Potassium Oxaliplatin
Study: NCT05070169

Intervention type: PROCEDURE
Intervention: Early Surgical Fixation vs. Delayed Surgical Fixation
Description: Evaluation of the reduction of the peri-operative blood loss in patients undergoing early surgical fixation (within 24 hours) of an intertrochanteric fracture under DOAC therapy compared to a retrospectively enrolled group of patients who underwent delayed surgical fixation (≥48 hours) of an intertrochanteric fracture under DOAC therapy.
Study: NCT06564467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMT202
Description: subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placrbo
Description: subcutaneous injection
Study: NCT06251154

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens 1
Description: Daily disposable silicone hydrogel contact lens (diameter=14.0mm) for 15 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens 2
Description: Daily disposable silicone hydrogel contact lens (diameter=14.1mm) for 15 minutes
Study: NCT06433765

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05494723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YB-1113
Description: Human umbilical cord tissue-derived mesenchymal stem cells (hUC-MSC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YB-1113
Description: Human umbilical cord tissue-derived mesenchymal stem cells (hUC-MSC)
Study: NCT06568666

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar spinal manipulation
Description: Lumbar spinal manipulation was performed in the lateral recumbent position and HVLA thrust was applied to the segment where dysfunction was detected. The spinal process was determined as the contact point and the direction of HVLA thrust was from posterior to anterior.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sacroiliac joint manipulation
Description: The participant lies on his/her side on the healthy side; the lower knee is in extension while the upper knee is flexed and placed in the popliteal fossa of the lower knee. The participant's hands are left free on the ribs at the lower level. The practitioner crosses the movement barrier with the stabilizing hand, allowing the tissues to relax. The practitioner performs HVLA thrust of the iliac bone into posterior or anterior rotation (in the opposite direction of dysfunction) with the stabilizing hand
Study: NCT06317337

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: focused ultrasound cavitation augmented with aerobic exercises
Description: Ultrasound cavitation single session per week along with the Aerobic exercises. Aerobic Exercise was Treadmill walk for 30 min with moderate intensity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: focused ultrasound cavitation augmented with aerobic exercises
Description: Ultrasound cavitation single session per week along with the Aerobic exercises. Aerobic Exercise was Treadmill walk for 30 min with moderate intensity
Study: NCT05480956

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SIRI Checklist
Description: A standardized checklist of clinical items to review by the attending hospitalist with participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Peer Recovery Coach
Description: Participants will receive the addiction medicine standard of care plus peer recovery coaching beginning while hospitalized and continuing for up to 1 month after randomization. As part of this study, Peer recovery coaches will initiate contact with patients weekly in person during the hospitalization and at the time of hospital discharge. The enhanced part of the peer coach is the post-hospital follow-up. Following discharge, contact will continue weekly in person, by phone, and/or via text messaging based on the participant's preferences for 1 month.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SIRI Checklist + Enhanced Peer Recovery Coach
Description: A standardized checklist of clinical items to review by the attending hospitalist with participants. Participants will receive the addiction medicine standard of care plus peer recovery coaching beginning while hospitalized and continuing for up to 1 month after randomization. As part of this study, Peer recovery coaches will initiate contact with patients weekly in person during the hospitalization and at the time of hospital discharge. The enhanced part of the peer coach is the post-hospital follow-up. Following discharge, contact will continue weekly in person, by phone, and/or via text messaging based on the participant's preferences for 1 month.
Study: NCT05489523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis 61 MG
Description: Tafamidis 61 mg by mouth daily for 12 months
Study: NCT04593589

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Submandibular Gland Stem Cell Transplantation
Description: Autologous transplantation of salivary stem cells (salisphere derived cells) cultured in vitro as obtained from submandibular glands after postoperative radiotherapy
Study: NCT06577090

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimacimab injection
Description: Nimacimab injection 200 mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimacimab injection
Description: Nimacimab injection 200 mg

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Nimacimab placebo injection
Description: matching nimacimab placebo injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nimacimab placebo injection
Description: matching nimacimab placebo injection

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: semaglutide injection
Description: semaglutide injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: semaglutide injection
Description: semaglutide injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg
Study: NCT04991116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TILD sub-cutaneous (SC) injection
Description: 1 mL injection of study medication
Study: NCT06389968

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light stimulation
Description: see arm description

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham light stimulation
Description: see arm description
Study: NCT06239792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Promotion Program
Description: SPP prioritizes increasing sleep duration and regularizing sleep-wake timing. The provider and youth review the youth's sleep pattern, based on sleep diary data collected before and during the program and actigraphy data collected at baseline. They discuss benefits to the current sleep pattern, reasons for changing sleep, and they create an action plan. Psychoeducation about healthy sleep is offered via a handout developed by our group. Youth and provider jointly select SPP strategies relevant to the contributors to poor sleep for each youth (e.g., time management, limiting weekend oversleep). In the second session they review progress and adjust the plan. Parents participate for part of each session to learn about their child's sleep and to discuss ways they can support their child to make the planned changes.
Study: NCT06569680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Mosunetuzumab will be administered via subcutaneous (SC) injection using a step-up dosing model. Participants will receive Mosunetuzumab on days 1, 8, and 15 of Cycle 1, and on day 1 of Cycles 2 through 8 as follows:~* Cycle 1 Day 1: 5mg~* Cycle 1 Day 8: 45mg~* Cycle 1 Day 15: 45mg~* Cycles 2 through 8, Day 1: 45mg
Study: NCT05510856

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Duloxetine 30mg / day for 12 cycles (up to 6 months)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 300 mg / day for 12 cycles (up to 6 months)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide 50 mg / day for 12 cycles (up to 6 months)
Study: NCT06243016

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High-Intensity Interval Training (HIIT) Breaks to Sitting
Description: HIIT Breaks: a 3.5-hour sitting will be interrupted every 30 min with 6-min HIIT Breaks. During sitting participants will engage in standardized sedentary activities. Each 6-min HIIT break comprises a one-minute warm-up, followed by a 2-minute high-intensity interval, one minute rest (sitting on a cycle ergometer) followed by another 2 minutes at high intensity.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Light-Intensity Interval Training (LIIT) Breaks to Sitting
Description: LIIT Breaks: a 3.5-hour sitting will be interrupted every 30 min with 6-min LIIT Breaks. Each 6-min LIIT break comprises a one-minute warm-up, followed by a 2-minute light-intensity interval, one minute rest (sitting on a cycle ergometer) followed by another 2-minute light-intensity interval.
Study: NCT05208944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-Thio-2'-Deoxyguanosine
Description: small molecule telomere targeting agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-Thio-2'-Deoxyguanosine
Description: small molecule telomere targeting agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-Thio-2'-Deoxyguanosine
Description: small molecule telomere targeting agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: programmed cell death protein 1 (PD-1) inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: programmed cell death protein 1 (PD-1) inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: programmed cell death protein 1 (PD-1) inhibitor
Study: NCT05465187

Intervention type: OTHER
Intervention: Non applicable
Description: Non applicable
Study: NCT05340426

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UKidney
Description: The intended clinical product is a kidney derived from a domestic pig that contains an intentional genomic alteration (IGA) to protect it after transplantation from the human immune response via inactivation of endogenous porcine genes responsible for expression of pig epitopes and inclusion of human transgenes to inhibit host immunogenic response.
Study: NCT04832204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib and Camrelizumab for Injection
Description: Apatinib 250mg, Qd, oral administration,SHR-1210 200mg, q3w one week later, intravenous administration, continuous administration until the disease progresses or an intolerable adverse reaction occurs.
Study: NCT06533202

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational Programme
Description: The objective of this type of programme is to equip individuals with the knowledge and skills required to navigate the challenges and capitalise on the opportunities presented by retirement. In particular, the programme strives to enhance the quality of life and attitudes towards retirement, elevate levels of life satisfaction, psychological flexibility, perceived social support and general health, self-efficacy and self-regulation, and mitigate stereotypes associated with ageing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Programme
Description: At the end of the baseline assessment, participants will receive instructions and recommendations to facilitate a positive and healthy transition to retirement, as part of an education programme. These will focus on the benefits of an active lifestyle and general guidelines to follow.
Study: NCT05464147

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DynamX Drug-Eluting Coronary Bioadaptor System
Description: DynamX Drug-Eluting Coronary Bioadaptor System Implantation in Coronary Artery Lesion
Study: NCT04912505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Run-in phase during one week with daily aspirin intake at 8 AM; visit 1: blood sampling at H24 and H2; intermediate phase (two weeks): daily aspirin intake at 8 PM; visit 2: blood sampling at H12; then daily intake of aspirin at the time preferred by the patient and study end visit 2 weeks after visit 2
Study: NCT05561998

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TalkingMats
Description: TalkingMats is a low-technology communication framework, to help people with communication difficulties to express their views. It uses a simple system of picture symbols, placed on a textured mat, that allow people to indicate their feelings about various options within a topic by placing the relevant image below a visual scale. Three sets of symbols are used, one set for the topics of the conversation, one set for the options within each topic and one set consisting of the value scale under which the options are placed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual conversation method
Description: The standard procedure during needs-assessment conversation and conversations planning the provision of home care services.
Study: NCT06483711

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle Kit
Description: The investigators will provide a kit to families that contains educational information, exercise equipment, and nutritional products.
Study: NCT05189860

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-MIC system
Description: This study aims to follow up patients already treated with a C-MIC System over a period of 2 years following the initial treatment with the device, to assess the long term results.
Study: NCT06535347

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information about scheduling a follow-up appointment
Description: Text message(s) will be sent following discharge from the emergency department, along with an after visit summary.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information about scheduling a follow-up appointment
Description: Text message(s) will be sent following discharge from the emergency department, along with an after visit summary.
Study: NCT05397119

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BW-1014: 25 µg rH5 in 20% NE - pipette - IN
Description: 20% Nanoemulsion and 25 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BW-1014: 50 µg rH5 in 20% NE - pipette - IN
Description: 20% Nanoemulsion and 50 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BW-1014: 100 µg rH5 in 20% NE - pipette - IN
Description: 20% Nanoemulsion and 100 µg recombinant H5 antigen administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: rH5 (100 µg) control - pipette - IN
Description: 100 µg recombinant H5 antigen (without adjuvant) administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Saline (Placebo) - pipette - IN
Description: Saline (negative control) administered intranasally by an electronic pipette (500µL) Two doses administered 4 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 IIV - IM
Description: 90 µg H5N1 IIV administered intramuscularly (1 mL) One booster dose administered 6 months following last immunization

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 IIV - IM
Description: 90 µg H5N1 IIV administered intramuscularly (1 mL) One booster dose administered 6 months following last immunization

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 IIV - IM
Description: 90 µg H5N1 IIV administered intramuscularly (1 mL) One booster dose administered 6 months following last immunization

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: H5N1 IIV - IM
Description: 90 µg H5N1 IIV administered intramuscularly (1 mL) One booster dose administered 6 months following last immunization